Rigel Pharmaceuticals, Inc.

• 3 Drug Catalysts to Watch in 2013

  By Brandy Betz - May 9, 2013 | Tickers: MNKD, MRK, PFE, RIGL, SNY

  Pharmaceutical investors: start your engines! We’re into the second quarter of 2013 and some major catalysts lurk right around the corner.

  Merck (NYSE: MRK) has a Food and Drug Administration meeting for a potential first-in-class insomnia treatment. The drug offers a better safety profile than the currently available treatments. MannKind (NASDAQ: MNKD)  returns with additional trial data that has delayed its anticipated diabetes inhalant. And Rigel Pharmaceuticals (NASDAQ: RIGLmore »)

• Are these Biotech Stocks a Buy After Thursday's News?

  By Brian Nichols - December 14, 2012 | Tickers: AZN, ONCY, RIGL

  Thursday was a big day for two biotechnology companies: Rigel Pharmaceuticals and Oncolytics Biotech (NASDAQ: ONCY). It was a day that investors have awaited, a day when both companies presented top-line results for each respective late-stage study. However, on this day, only one group of investors would be happy. With that being said, is there upside following the market leading movement for either of these two companies?

  Fostamatinib Might be more »

• Healthcare Hedge Fund is Selling This Pharma Stock, Should You Too?

  By Meena Krishnamsetty - October 8, 2012 | Tickers: ALKS, HSP, NKTR, PCRX, RIGL

  Between April and June of this year, Orbimed Advisors sold 18% of its shares of Pacira Pharmaceuticals (NASDAQ: PCRX), finishing the second quarter with exactly 2 million shares in its portfolio. According to a more recent 13F filing with the SEC, Orbimed has continued selling shares during the third quarter, and as of September 25^th owned just over 1.6 million shares, placing it under the 5% ownership mark more »

• J.P. Morgan Healthcare Conference Schedule: Day One

  By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

  The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

  I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)